Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy

Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy

Abstract Background Neoadjuvant chemotherapy is the standard treatment for local advanced breast cancer administered to shrink tumors and destroy undetected metastatic cells, thereby facilitating subsequent surgery. Previous studies have shown that AR may be used as a prognostic predictor in breast...

Full description

Bibliographic Details
Main Authors:	Zhendong Shi, Yingxue Liu, Shichao Zhang, Shuanglong Cai, Xu Liu, Jie Meng, Jin Zhang
Format:	Article
Language:	English
Published:	Springer 2023-04-01
Series:	Discover Oncology
Subjects:	Breast cancer Androgen receptor Adjuvant chemotherapy Pathological complete response Disease free survival
Online Access:	https://doi.org/10.1007/s12672-023-00660-z

Similar Items

Effect of adjuvant chemotherapy on the oncological outcome of rectal cancer patients with pathological complete response
by: Jianguo Yang, et al.
Published: (2024-01-01)

Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy before Surgery for Treating Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis
by: Chun-Kai Liao, et al.
Published: (2022-05-01)

A case of retroperitoneal dedifferentiated liposarcoma successfully treated by neoadjuvant chemotherapy and subsequent surgery
by: Yukihiro Yokoyama, et al.
Published: (2020-05-01)

Multiparametric Contrast-Enhanced Ultrasound in Early Prediction of Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival in Breast Cancer
by: Caifeng Wan, et al.
Published: (2023-07-01)

Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls
by: Kai CC Johnson, et al.
Published: (2023-12-01)

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy
by: Jiayi Li, et al.
Published: (2022-02-01)

Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE)
by: Chang Woo Kim, et al.
Published: (2018-05-01)

Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy
by: Anna Weiss, et al.
Published: (2018-04-01)

Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion
by: Ahmed Eldefrawy, et al.
Published: (2012-01-01)

Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
by: Serhat Sekmek, et al.
Published: (2023-11-01)

Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy
by: Youzhao Ma, et al.
Published: (2023-03-01)

The Prognostic Significance of Postoperative Adjuvant Chemotherapy in the Population Aged 75 Years and Older with Stage II–III Colorectal Cancer: A Retrospective Multi-Center Cohort Study
by: Liu L, et al.
Published: (2023-08-01)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
by: Shuling Zhou, et al.
Published: (2023-02-01)

Impact of adjuvant chemotherapy on outcomes in appendiceal cancer
by: Bhaskar C. Kolla, et al.
Published: (2020-05-01)

Association of Various Factors in Terms of Pathological Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
by: Anum Zargham, et al.
Published: (2023-05-01)

Nomogram to Predict Distant Metastasis Probability for Pathological Complete Response Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy
by: Jiang T, et al.
Published: (2021-06-01)

Predictive Factors and Prognostic Value of Pathologic Complete Response of Internal Mammary Lymph Nodes in Breast Cancer After Neoadjuvant Chemotherapy
by: ZHANG Weifang, et al.
Published: (2022-12-01)

Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy
by: Rui Sha, et al.
Published: (2021-09-01)

Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer: A Multicentric Propensity Score Study
by: Antoni Llueca, et al.
Published: (2023-08-01)

Pathological complete response following neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma
by: Yoshitaka Shimamaki, et al.
Published: (2024-02-01)

Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis
by: Samuel Rosner, MD, et al.
Published: (2022-09-01)

Enhanced Efficacy of Neoadjuvant Chemotherapy with Nab-Paclitaxel and Platinum for Locally Advanced Cervical Cancer
by: Yu XL, et al.
Published: (2021-12-01)

Identification of Ferroptosis-Related Prognostic Signature and Subtypes Related to the Immune Microenvironment for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
by: Yuhao Xu, et al.
Published: (2022-05-01)

Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival
by: Gilles Houvenaeghel, et al.
Published: (2024-02-01)

Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer
by: Yuanyuan Chen, et al.
Published: (2022-06-01)

Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers
by: Ling-Ming Tseng, et al.
Published: (2023-12-01)

Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study
by: Maximilien Rogé, et al.
Published: (2022-08-01)

Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
by: Qing Hu, et al.
Published: (2021-06-01)

Effect of Adjuvant Chemotherapy on DFS for Patients with Stage I NSCLC
by: Shengzu PENG, et al.
Published: (2017-06-01)

Predicting the response to neoadjuvant chemotherapy for breast cancer: wavelet transforming radiomics in MRI
by: Jiali Zhou, et al.
Published: (2020-02-01)

Impact of adjuvant chemotherapy on patients with ypT0–2 ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital
by: Christian Galata, et al.
Published: (2018-08-01)

The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
by: Mina M. G. Youssef, et al.
Published: (2021-02-01)

Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery
by: Chang Gon Kim, et al.
Published: (2017-09-01)

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
by: Witali Aswolinskiy, et al.
Published: (2023-11-01)

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
by: Ruo-Xi Wang, et al.
Published: (2022-10-01)

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
by: Tetsuya Isaka, et al.
Published: (2022-09-01)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
by: I.P.C. Buzatto, et al.

Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)
by: Simon Peter Gampenrieder, et al.
Published: (2019-01-01)

Survival of GEJ and gastric adenocarcinoma patients admitted at Imam Khomeini and Aram oncology clinic and treated with preoperative EOX chemotherapy
by: ALI FARAHAT, et al.
Published: (2023-06-01)

Delta-Radiomics Based on Dynamic Contrast-Enhanced MRI Predicts Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
by: Liangcun Guo, et al.
Published: (2022-07-01)